Gene Sequence explained: this guide covers what it means, who it applies to, the step-by-step process, documents required, fees, due dates and penalties in India — so you can stay compliant with confidence and avoid costly mistakes.
Paragraphs 6 to 9 of the Biotechnology Patent Guidelines (March 2013) are the patentability tests for gene and protein inventions. They say how the examiner searches sequences, when a sequence claim lacks novelty, when a small change in a sequence is obvious, and what use a gene or fragment must disclose to be industrially applicable.
The examiner searches by sequence as well as by keyword and class (para 6). A prior disclosure of the same sequence anticipates a sequence claim even if its function was unknown (7.2). A mutation that gives no unexpected property is obvious (para 8). A gene or fragment needs a specific, substantial and credible use; a use as a mere "gene probe" does not qualify (para 9, 9.1). The Guidelines are the Patent Office's guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as now in force prevail.
The Office revises its guidelines, so check the current version on ipindia.gov.in. This document dates from March 2013. Its references to the Manual (Chapter 8) point to what is now Chapter 9 of the 2019 Manual; see our articles on novelty and inventive step. If a sequence claim has drawn a novelty or utility objection, a patent objection reply should use the points below.
Prior art search (paragraph 6)
The examiner frames a comprehensive search combining key words, classification and sequences, across patent and non-patent databases. Where a specification discloses nucleotide or amino acid sequences, the sequence listing must also be filed in electronic form under rule 9(1), and in a computer-readable format. The examiner then searches sequence databases available to the Office and openly available ones, using tools such as BLAST and FASTA.
The practical point is that the sequence listing is part of how the application is searched. A listing that is missing, in the wrong format, or inconsistent with the claims slows examination.
Novelty (paragraph 7)
Novelty of biotechnological inventions is assessed as for other inventions, under section 13 read with sections 29 to 34, and the Manual's novelty procedure. The Guidelines repeat that a published application with an earlier priority date counts as prior claiming.
Product-by-process claims (7.1)
A claim to a product defined by how it is made is anticipated by any prior disclosure of that product, whatever the process. The Guidelines' examples are a polypeptide made by a method, a transgenic micro-organism obtained by a method and a plasmid obtained by a method. Such claims are admissible only if the products themselves meet the patentability requirements. Novelty in the process does not make the product novel; novelty can only be shown by technical evidence that process changes give distinct products with different properties from known ones.
Sequence claims (7.2)
| Situation | Position in the Guidelines |
|---|---|
| A polynucleotide sequence that was available before the priority date, for example in a library, even if its function was unknown | Lacks novelty |
| A specific fragment of a polynucleotide | May be novel, but must still pass inventive step and section 3 |
| A prior disclosure of the same sequence without any activity | Prima facie anticipates, on the reasoning that the earlier sequence inherently has the claimed activity |
| A prior sequence that does not exactly match the claimed sequence | Does not anticipate, but is relevant to inventive step and section 3 |
Combination and composition claims (7.3)
The Guidelines say combinations usually escape the novelty question and are dealt with under inventive step or section 3, but where the combination is already in the public domain it is dealt with under novelty. Their example is a composition against diphtheria toxin containing antibodies from chicken egg yolk, preservatives and stabilisers, where the prior art disclosed a composition with such antibodies, a carrier and additives and the same preparation process from immunisation to purification. The claim lacks novelty.
Inventive step (paragraph 8)
The Guidelines refer to the Manual's inventive step procedure and the definition in the Act, and give five illustrations.
| Example | Scenario | Outcome | Reason |
|---|---|---|---|
| IL-3 sequence | A DNA sequence encoding a human protein with a proline residue at position 8 where the prior art has a serine | Lacks inventive step | The proteins are variants of one family; a single amino acid change does not normally change function unless it is in a critical region; no evidence of different properties |
| Oligosaccharide process | A process using two named micro-organisms together, where one document teaches one organism and another teaches that the second consumes glucose | Lacks inventive step | The skilled person would be motivated to combine them to separate sugars and raise yield and purity |
| Plasmid removal | A method using silver nanoparticles at sub-inhibitory concentrations to remove plasmids from bacteria; the prior art shows nanoparticles increase membrane permeability and leakage of cell contents | Lacks inventive step | The prior art would motivate a skilled person with reasonable expectation of success to try it for plasmid removal |
| Pro-insulin | A shorter connecting peptide of two amino acids, where the prior art has a different two-residue peptide; the applicant showed higher yield | Obvious | The yield difference was not an unexpected property |
| Interferon | A DNA sequence encoding one interferon subtype, where the prior art has a close subtype | Not obvious | The claimed protein was thirty times more potent in antiviral activity than its prior analogue |
The rule drawn is that a mutation in a known sequence is obvious unless it gives an unexpected property, and that obviousness can be shown from a single document or a mosaic of documents.
Industrial application (paragraph 9)
The Guidelines tie industrial applicability to usefulness (section 64(1)(g)) and say the specification should disclose usefulness in a distinct and credible manner. For genes, whatever the ingenuity in finding a sequence, a patent for it or for the protein it encodes needs disclosure of how it can be used. The use must be specific, substantial and credible, not speculative.
Two examples:
- A viral polypeptide with an antigenic determinant, whose use was established in the specification, was allowable; but a second claim to a vast number of polypeptides by sequence, with no use established for them, was not allowable for lack of industrial applicability.
- A receptor protein whose function was only predicted from structure and homology, with no ligand disclosed, had a use that was speculative, so it was not industrially applicable.
Fragments and ESTs (9.1)
Fragments and expressed sequence tags are allowable if they also satisfy usefulness. A use only as a "gene probe" or "chromosome marker" is not enough; a credible, specific and substantial use must be disclosed, for example as a probe to diagnose a specific disease.
What the examiner checks, and what to file
| Examiner's question | What the applicant should show |
|---|---|
| Is the same sequence in the prior art, even without a function? | That the claimed sequence differs, or a narrower claim such as a specific fragment |
| Is the product-by-process claim to a new product? | Technical evidence that the product differs in properties |
| Does a point mutation give an unexpected property? | Comparative data showing the unexpected property, with a quantified difference |
| Is a use disclosed that is specific, substantial and credible? | The use, with supporting data, in the description |
| Is the sequence listing filed correctly? | A listing in electronic, computer-readable form under the Rules |
A worked example (invented)
Harit Biosciences claims a DNA sequence that differs by one base from a published crop gene, saying the protein gives drought tolerance. The examiner objects that a single change does not alter function (the pattern of the IL-3 example) and that the use is not shown. Harit files its specification's field trial results, which show a marked difference in survival under water stress against the published sequence, and argues that the change sits in a critical region. The reply supplies the unexpected property and the credible use that paragraphs 8 and 9 look for.
Common lapses
- Claiming a sequence already in a database and arguing it was never known to have a function.
- Claiming a long list of sequences when the specification supports a use for only some.
- Describing an EST's use only as a probe or marker.
- Treating a process difference as a product difference in a product-by-process claim.
Need help with a sequence or biotech novelty objection?
These objections turn on the exact sequence comparison and the data in the specification. Our team can check the sequence listing against the cited art and prepare the reply. See patent objection reply, and read next on the section 3(b) to (e) exclusions.
Key takeaways
- Sequence listings are part of the search; file them in the required electronic form.
- A prior disclosure of the same sequence anticipates even without a known function.
- A mutation with no unexpected property is obvious.
- A gene or protein needs a specific, substantial and credible use.
- ESTs described only as probes or markers do not have industrial application.
Read next
- Biotechnology Patent Guidelines 2013, paragraphs 1 to 5: scope and kinds of claims
- Biotechnology Patent Guidelines 2013, paragraphs 10 to 13: section 3(b), (c), (d) and (e)
- Manual Chapter 9: how novelty is assessed
- Manual Chapter 9: inventive step
Disclaimer: Based on the manuals and guidelines published by the Office of the Controller General of Patents, Designs and Trade Marks that are named in the article, as consulted on 4 October 2026. They are guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as amended (including the 2024 amendment rules) prevail, and the current versions on ipindia.gov.in should be checked. This article is general information, not legal advice; check the official text before acting.